Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Learn more about HealthTree
Using Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma with Peter Voorhees, MD, Levine Cancer Institute image

Using Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma with Peter Voorhees, MD, Levine Cancer Institute

Posted on: May 18, 2021
Play Episode
Also available on
play podcast in spotifySpotify play podcast in apple podcastsApple Podcasts play podcast in youtubeYoutube
Description

Peter Voorhees, MD
Levine Cancer Institute - Atrium Health
Interview Date: May 18, 2021

Quad therapies (four combined myeloma treatments) are becoming more popular, even for newly diagnosed myeloma patients. In this show, Dr. Peter Voorhees of the Levine Cancer Institute shares details about how the addition of a monoclonal antibody like daratumumab, isatuximab or elotuzumab may be used in combination with other standard myeloma treatments for newly diagnosed patients. This is a major shift for newly diagnosed patients to use these monoclonal antibodies in earlier lines of therapy instead of reserving these new treatment drug classes for later use. 

Thanks to our episode sponsor

User uploaded media

Overview

Peter Voorhees, MD
Levine Cancer Institute - Atrium Health
Interview Date: May 18, 2021

Quad therapies (four combined myeloma treatments) are becoming more popular, even for newly diagnosed myeloma patients. In this show, Dr. Peter Voorhees of the Levine Cancer Institute shares details about how the addition of a monoclonal antibody like daratumumab, isatuximab or elotuzumab may be used in combination with other standard myeloma treatments for newly diagnosed patients. This is a major shift for newly diagnosed patients to use these monoclonal antibodies in earlier lines of therapy instead of reserving these new treatment drug classes for later use. 

Thanks to our episode sponsor

User uploaded media

On this episode
Healthtree contact Peter Voorhees, MD

Peter Voorhees, MD

Peter Voorhees, MD, is Director of Outreach and Clinical Operations for Hematologic Malignancies and a Member of the Plasma Cells Disorder Program at the Levine Cancer Institute in Charlotte, North Carolina. Dr. Voorhees is an internationally recognized thought leader in multiple myeloma whose research focuses on the clinical development of novel therapeutic strategies for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. He is board certified in Hematology and a member of the American Society of Hematology, American Society of Clinical Oncology and International Myeloma Working Group. He is also a member of the Multiple Myeloma Committee of the Alliance Cooperative Group. He has published numerous original articles, reviews and book chapters in multiple myeloma. He received his medical degree from the University of Michigan, continued his postgraduate studies with an internal medicine residency/chief residency at the University of Wisconsin, and completed a hematology-oncology fellowship at the University of North Carolina at Chapel Hill. Prior to joining the Levine Cancer Institute, he was an Associate Professor in the Department of Internal Medicine, Division of Hematology-Oncology, at the University of North Carolina at Chapel Hill where he led their Multiple Myeloma Program.
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Transcript

Related Content